TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Enhanced Medication Reconciliation For Serious Mental Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current insurer is UPMC Health Plan~* Currently active in CRS clinic~* Prescribed four or more medications as indicated by pre-study Health Plan Medication List~* Able to provide informed consent for present study~Exclusion Criteria:~* Not competent to give informed consent in the opinion of the investigator~* Having had a previous medication reconciliation by the clinical pharmacist

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enhanced Medication reconciliation (Type: EXPERIMENTAL): Medication reconciliation with pharmacist using electronic health records, pharmacy dispensing data and Sano Patient Medication Profile(TM)
- Standard Medication reconciliation (Type: NO_INTERVENTION): Medication reconciliation with pharmacist using electronic health records and pharmacy dispensing data only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients age 12 and older and 45 kg or more~2. Suspected or confirmed influenza (Appendix A)~3. Requirement for ICU admission due to respiratory distress or critical illness defined as one of:~   1. Inspired oxygen need of \>50% for at least 4 hours (For FiO2 for non-intubated patients see Appendix B)~  2. mechanical ventilation~  3. Patient is receiving inotrope or vasopressor~4. Negative b-HCG test or negative bedside urine test pending a confirmatory b-HCG test for pregnancy in women of childbearing age (12-60 years of age) will allow study entry~Exclusion Criteria:~1. Inability to obtain consent~2. Patients receiving more than two doses of 150 mg or higher oseltamivir in 36 hours before study entry~3. Patients having received more than 3 doses of 75 mg oseltamivir immediately in 36 hours before study entry~4. Age less than 12 years, or age \<16 and weight less than 45 kg~5. Unlikely to absorb enteral study drug (e.g. patients with partial or complete mechanical bowel obstruction, intestinal ischemia, infarction, and short bowel syndrome)~6. Known allergy or hypersensitivity to oseltamivir~7. Pregnancy or breast feeding~8. Previous enrollment in current study~9. Concurrent involvement in an RCT examining an antiviral agent including other neuraminidase inhibitors, interferon-a and/or ribavirin~10. Chronic renal failure requiring chronic hemodialysis~11. Severe chronic liver disease (Child-Pugh Score 11-15)~12. Anticipated death within 24 hours as judged by attending physician or local PI~13. Patient carrying do not intubate order (a no CPR or no defibrillate or no chest compressions order alone is allowed)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Oseltamivir dose 75 mg bid (Type: ACTIVE_COMPARATOR): Standard dosing
- High Dose Oseltamivir arm 225mg bid (Type: EXPERIMENTAL): High dose arm of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: Validity, Acceptability and Impact on Linkage to Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Indication of hepatitis C screening~* Active or ex-injection drug user~Exclusion Criteria:~* Known hepatitis C infection~* Unknown HIV status and patient refusing to HIV testing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Patients will be tests with both the standard algorithm and the Oraquick HCV Rapid Antibody Test
- Group B (Type: ACTIVE_COMPARATOR): Patients will be tested only with the standard algorithm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects age 18 and over and of either gender.~2. Scheduled to receive CT scan with intravenous contrast dye.~3. Non diabetics or subjects with type 1 or 2 diabetes mellitus~4. Written informed consent.~5. Subjects who are on diuretics and non-steroidal inflammatory agents will not be excluded.~6. Subjects who have received n-acetylcysteine or sodium bicarbonate pre CT scan will not be excluded~Exclusion Criteria:~1. Pregnant or lactating women.~2. End-stage renal disease (on hemodialysis or peritoneal dialysis)~3. A known history of acute renal failure~4. Subjects receiving glucophage/metformin or glucovance~5. Subjects who cannot give written informed consent.~6. Subjects receiving peritoneal dialysis or hemodialysis.~7. Subjects enrolled in another investigational drug study ≤ 30 days of enrollment into the present study.~8. Subjects with a known hypersensitivity or anaphylaxis to contrast dye or iodine.~9. Subjects with known hypersensitivity or anaphylaxis to erythropoietin, mammalian-cell derived products, or human albumin.~10. Age \< 18 years~11. Use of any erythropoietin replacement or transfusion within the prior 3 days~12. Baseline Hemoglobin \> 12.0 g/dL~13. Uncontrolled hypertension, systolic BP \> 180 mmHg or diastolic BP \> 110 mmHg in any recording in the past 24 hours.~14. Evidence of hemodynamic instability~15. Subject unable to follow protocol due to mental incompetence or other reason~16. Inaccessibility of medical record~17. Subjects with a history of MI, CVA, active angina or unstable angina within the past three months~18. Subjects with a history of current malignancy, where current malignancy is defined as subjects undergoing treatment with chemotherapy or radiation therapy, subjects with known metastatic disease, and those with terminal malignant disease.~19. Subject with any known history of seizure disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erythropoeitin (Type: PLACEBO_COMPARATOR): Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* newborns and infants with weight lower than 10 kg undergoing cardiac surgery with extracorporeal circulation:~* informed consent signed by both parents or legal guardian.~Exclusion Criteria:~* emergency surgery;~* known congenital coagulopathy or suspected based on anamnesis;~* participation to other clinical trials;~* known hypersensitivity to components and excipients of FFP , prothrombin complex concentrate or fibrinogen concentrate.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- ZEPLAST (Type: EXPERIMENTAL): In case of bleeding and:~* CT INTEM \> CT HEPTEM by 25% : give protamine 0.25 mg/kg;~* MCF FIBTEM \< 8 mm : give Fibrinogen Concentrate 30 mg/kg;~* CT EXTEM \> 100 s : give Prothrombin Complex Concentrate 20 mg/kg.
- Control (Type: ACTIVE_COMPARATOR): In case of bleeding and:~* CT INTEM \> CT HEPTEM by 25% : give protamine 0.25 mg/kg;~* fibrinogen and/or thrombin generation deficiency : give FFP 10-20 ml/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sternal Closure With STERNUMFIX in Patients With High Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Patients undergoing elective cardiac surgery with a median sternotomy~* Age \>18 years~* Male and female sex~* Informed consent~* Patients with high risk for sternal wound complications~Patients are designated as high risk patients if they have either:~* one or more major risk factors or~* four or more minor risk factors.~Major risk factors are:~* Obesity: BMI \> 30.~* Diabetes: intake of oral anti-diabetic drugs and/or insulin at time of surgery.~* COPD: history of chronic coughing plus expectoration for at least 3 months by at least two consecutive years, plus evidence of restrictive pattern at spirometry.~* Planned BITA: bilateral use of thoracic artery~* Age \> 75 years~Minor risk factors are:~* History of smoking;(minimum of 1 year of history of smoking)~* Hyperlipoproteinaemia (as stated in the patient data)~* Planned surgery is a CABG~* Patient is on dialysis~* Repeat sternotomy~* Left ventricular ejection fraction \< 30% (as stated in the patient data)~* Male sex~Exclusion:~* Active infection~* Participation in a pharmaceutical clinical study or any trial with interfering endpoints within the last 30 days~* Pregnancy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sternumfix (Type: EXPERIMENTAL): sternotomy closure with Sternumfix
- Steel wire (Type: ACTIVE_COMPARATOR): sternotomy closure with steel wire

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Active Surveillance Post-Approval Atudy of the Stelkast Surpass Acetabular System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primary hip arthroplasty~* Skeletal maturity~* Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, congenital hip dysplasia, and traumatic arthritis~Exclusion Criteria:~* The Stelkast Surpass Acetabular System is contraindicated in patients with the following conditions: Overt or latent infection in or around the hip joint, insufficient bone stock to allow appropriate insertion and fixation of the prosthesis, insufficient soft tissue integrity to provide adequate stability, muscle laxity or inadequate soft tissue for proper function and healing, mental or neuromuscular disorders that do not allow control of the affected joint, revision hip arthroplasty, inflammatory hip joint disease, and neuropathic hip joint disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stelkast Surpass Patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of diabetic neuropathy or failed back syndrome with neuropathic symptoms~* Age 18-80~* Taking a stable dose of gabapentin or pregabalin~Exclusion Criteria:~* Pregnant women or women of child-bearing potential not willing to practice a reliable form of birth control~* Allergy to donepezil or other piperidine derivatives (including fentanyl, alfentanil, sulfentanil, remifentanyl, demerol, tramadol, loperamide, diphenoxylate, betaprodine, alphaprodine, ethopropazine, anileridine, piminodine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP),loratadine, fexofenadine~* Unstable medical conditions including cardiac, pulmonary, renal or hepatic diseases that, in the opinion of the investigator, would preclude patients from finishing the trial~* Any person with pending litigation~* A history of major psychosis requiring hospitalization within the last three years~* Non-English speaking, illiterate, unable to comprehend consent~* Lack of contact information~* Uncontrolled narrow-angle glaucoma~* Currently being treatment with thioridazine (Mellaril)~* Patients taking opioids will be excluded if they are taking a dosage that exceeds an equivalent of 30 mg of morphine per day~* Patients taking more than one regular (not rescue) medication for pain~* Patients taking donepezil for dementia~* Patients with a baseline pain score less than 2 (0-10 scale) or greater than 8 (0-10) will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: EXPERIMENTAL): donepezil 5 mg every day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (sugar pill) every day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In- and outpatients of either sex~* Able to comply with the protocol~* Having given their written informed consent of their own free will~* Total BPRS (PANSS-derived, 1-7 points) minimum 36 points at baseline~* Schizophrenic or schizophreniform disorder according to DSM-IV criteria (295.10, .30, .40, .90)~* Definite right-handedness (according to the modified Edinburgh Handedness Inventory)~* Age 18 - 50 years~Exclusion Criteria:~* Co-morbid psychiatric axis I disorder (DSM-IV) other than schizophrenia~* Axis II disorder according to DSM-IV~* Present or past history of substance and drug dependence (including alcohol dependence)~* Participation in a clinical trial within the previous three months~* Lack of insight~* Suicidal ideations or aggression against others~* Consumption of caffeine-containing beverages within 6 hours before assessments~* Clinically significant findings in ECG or EEG~* Known intolerance against neuroleptics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): Haloperidol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diagnosis of ON With or Without MS or NMOSD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ages 18-90 years~2. Signed informed consent~3. Have been diagnosed with optic neuritis (ON) only, MS and ON, or NMOSD and ON~4. Have had at least one previous test to track optical nerve function~Exclusion Criteria:~1. Are pregnant or nursing~2. Are children (age \<18 years)~3. Do not have a diagnosis of optic neuritis (ON)~4. Have a diagnosis of MS or NMOSD without a diagnosis of ON as well

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Optic neuritis diagnosis only (Type: None): Patients who have a diagnosis of optic neuritis, without a diagnosis of MS or NMOSD.
- ON and multiple sclerosis (Type: None): Patients who have a diagnosis of optic neuritis AND multiple sclerosis.
- ON and NMOSD (Type: None): Patients who have a diagnosis of optic neuritis and neuromyelitis optica spectrum disorder.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven renal cell cancer with metastases; pathology from either primary or metastatic tumor; no histologic subtype restriction~* Evidence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or evaluable disease~* Eastern Cooperative Oncology Group (ECOG) performance score 0 to 1~* Hemoglobin \>= 9 gram/dL~* Common Terminology Criteria for Adverse Events (CTCAE) fatigue levels pre-treatment \< 2~* Signed and dated informed consent~Exclusion Criteria:~* Greater than 2 previous systemic treatments for RCC~* Heart failure, New York Heart Association (NYHA) class 3 and 4~* Unstable angina (defined as ongoing use of nitrates or cardiac ischemia in the prior 6 months)~* Arrhythmia uncontrolled by medication~* Hypertension (\> 160/90 mmHg) not controlled with medical management~* Brain metastases or previous cranial radiation, leptomeningeal cancer~* Surgery within 2 weeks of study entrance~* History of stroke, myasthenia gravis, multiple sclerosis, polyneuropathy~* Pregnancy or breast feeding~* Central-nervous system active medications, intake or withdrawal of which lowers seizure threshold (determination made in consultation with study's responsible treating physician)~* Any history of epilepsy, convulsion or seizure~* Medication-resistant epilepsy in a first-degree relative~* Cochlear implants or internal pulse generators or cardiac pacemakers or intracardiac lines~* Metallic implants in the vicinity of discharging coil in the head or cervical spine~* Unexplained fainting spells/syncope or multiple concussions~* History of severe head trauma (followed by loss of consciousness)~* Implanted brain or spinal cord electrodes/stimulation~* Medication infusion device~* Frequent/severe headaches or severe migraines~* Past or current medical history of diagnosed or undiagnosed tinnitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive care (sunitinib malate, neuromuscular testing) (Type: EXPERIMENTAL): Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥18 years of age.~* Histologically confirmed diagnosis of a solid tumor malignancy documented by cytology or biopsy.~* Presence of metastatic disease.~* Hemoglobin value between ≥8.0 to \<11.0 g/dL (≥80 to \<110 g/L).~* ≥28 days must have elapsed (prior to pre-dose red blood cell mass / plasma volume test) since previous treatment with erythropoiesis-stimulating agent (including concurrent treatment with intravenous \[IV\] iron).~* ≥28 days must have elapsed (prior to Day 1) since the last red blood cell transfusion and receipt of ≤2 units of blood in the past 56 days (prior to Day 1).~* Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 1.~Exclusion Criteria:~At the time of screening, participants who have any grade ≥3 toxicity (according to the currently active minor version of NCI CTCAE v4.0) except for the following disease-related toxicities:~* Hematological events - anemia, thrombocytopenia, neutropenia~* Non-hematological events - nausea, vomiting, fatigue, muscle or bone/joint pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sotatercept (Type: EXPERIMENTAL): Participants will receive a single 35 mg dose of sotatercept by subcutaneous (SC) injection on Day 1, Day 43, and Day 85.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of a Probiotic on Hepatic Steatosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult-onset diabetes~* Liver biopsy in the previous 2 months with diagnosis of fatty liver and fibrosis stage F2-F3~Exclusion Criteria:~* There are multiple exclusion criteria.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility